Oxytocin Formulation

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Oxytocin Formulation

Manufacturer or supplier’s details
Company : MSD
Address : No. 485 Jing Tai Road
           Pu Tuo District - Shanghai - China 200331
Telephone : 908-740-4000
Emergency telephone number : 86-571-87268110
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

2. HAZARDS IDENTIFICATION

Emergency Overview
Appearance : liquid
Colour : No data available
Odour : No data available

Not a hazardous substance or mixture.

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Not classified based on available information.

Environmental hazards
Not classified based on available information.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture
Components
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Oxytocin Formulation

Version 1.4
Revision Date: 2020/10/10
SDS Number: 3447180-00005
Date of last issue: 2019/09/13
Date of first issue: 2018/09/26

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytocin, monoacetate (salt)</td>
<td>6233-83-6</td>
<td>&gt;= 0.0003 &lt; 0.0025</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: None known.
Protection of first-aiders: No special precautions are necessary for first aid responders.
Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.
Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.
Hazardous combustion products: No hazardous combustion products are known

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters: Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling
Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
- Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact:
- Oxidizing agents

Storage
Conditions for safe storage:
- Keep in properly labelled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

Packaging material:
- Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytocin, monoacetate (salt)</td>
<td>6233-83-6</td>
<td>STEL</td>
<td>50 ng/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>60 ng/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
- Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
- All engineering controls should be implemented by facility
design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

**Personal protective equipment**

- **Respiratory protection**: No personal respiratory protective equipment normally required.
- **Eye/face protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- **Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hand protection**

- **Material**: Chemical-resistant gloves
- **Remarks**: Consider double gloving.
- **Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance**: liquid

**Colour**: No data available

**Odour**: No data available

**Odour Threshold**: No data available

**pH**: No data available

**Melting point/freezing point**: No data available
**10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Oxytocin Formulation

11. TOXICOLOGICAL INFORMATION

Exposure routes
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Oxytocin, monoacetate (salt):
Acute oral toxicity
- LD50 (Mouse): > 514 mg/kg
- LD50 (Rat): > 21 mg/kg

Acute toxicity (other routes of administration)
- LD50 (Mouse): > 514 mg/kg
  Application Route: Subcutaneous
- LD50 (Mouse): 5.8 mg/kg
  Application Route: Intravenous
- LD50 (Rat): > 21 mg/kg
  Application Route: Subcutaneous
- LD50 (Rat): 2.3 mg/kg
  Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:

Oxytocin, monoacetate (salt):
Genotoxicity in vitro
- Test Type: Chromosomal aberration
  Test system: Human lymphocytes
  Result: negative
Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

Components:

Oxytocin, monoacetate (salt):
Effects on foetal development: Test Type: Development
Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: NOAEL: 1 mg/kg body weight
Result: No effects on foetal development

Reproductive toxicity - Assessment: May damage the unborn child.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Oxytocin, monoacetate (salt):
Species: Rat
LOAEL: 5 µg/kg
Application Route: Subcutaneous
Exposure time: 5 Days
Target Organs: Endocrine system

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Oxytocin, monoacetate (salt):
Inhalation:
Target Organs: Central nervous system
Symptoms: behavioral abnormalities
Target Organs: Cardio-vascular system
Symptoms: Increased heart rate, May cause cardiac arrhythmia, hypotension, tachycardia, flushing
Target Organs: Gastrointestinal tract
Symptoms: Nausea, Vomiting

Ingestion:
Target Organs: Central nervous system
Symptoms: behavioral abnormalities
Target Organs: Cardio-vascular system
Symptoms: Increased heart rate, May cause cardiac arrhythmia,
Oxytocin Formulation

Target Organs: Gastrointestinal tract
Symptoms: Nausea, Vomiting

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
Oxytocin, monoacetate (salt):

Ecotoxicology Assessment
Acute aquatic toxicity: Toxic effects cannot be excluded
Chronic aquatic toxicity: Toxic effects cannot be excluded

Persistence and degradability
No data available

Bioaccumulative potential

Components:
Oxytocin, monoacetate (salt):
Partition coefficient: n-octanol/water: log Pow: 6.27

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations
GB 6944/12268
Not regulated as a dangerous good

Special precautions for user
Not applicable

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:

<table>
<thead>
<tr>
<th>Inventory</th>
<th>Determination</th>
</tr>
</thead>
<tbody>
<tr>
<td>AICS</td>
<td>not determined</td>
</tr>
<tr>
<td>DSL</td>
<td>not determined</td>
</tr>
<tr>
<td>IECSC</td>
<td>not determined</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Further information


Date format: yyyy/mm/dd

Full text of other abbreviations

AICIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships;
Oxytocin Formulation

Version 1.4
Revision Date: 2020/10/10
SDS Number: 3447180-00005
Date of last issue: 2019/09/13
Date of first issue: 2018/09/26

n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN